Exicure Inc. is a biotechnology company focused on developing innovative therapies based on its proprietary SNA technology, which utilizes programmable RNA to target and modulate gene expression in various diseases. The company's primary efforts are aimed at treating genetic disorders and cancers by delivering therapeutic agents that can precisely interact with specific RNA molecules. Through advancing its scientific research and clinical development, Exicure aims to address unmet medical needs and improve treatment outcomes for patients. Read More
Gainers Exicure (NASDAQ:XCUR) stock rose 38.4% to $2.38 during Tuesday's after-market session. The market value of their outstanding shares is at $10.5 million. Catheter Precision (AMEX:VTAK) stock moved upwards
Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Exicure, Inc. (NASDAQ: XCUR) breached their fiduciary duties to shareholders.
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR) a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that, as of July 1, 2025, the Company regained compliance with the periodic filing requirement for The Nasdaq Stock Market under Listing Rule 5250(c)(1) (the “Rule”) based on the filing of its periodic reports on Form 10-Q to the United States Securities and Exchange Commission for the fiscal quarter ended March 31, 2025. The Company has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming compliance with the Rule and stating that the matter has been resolved.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). Topline results from the study are expected in the fourth quarter of 2025.
